Whalesbook
Indian Pharmaceutical Market Shows Robust Growth in November 2025
The Indian pharmaceutical market has demonstrated significant resilience, reporting an 8.6% year-over-year growth in November 2025. This positive performance was achieved despite a high base of 10.7% growth recorded in November 2024, according to a Kotak Institutional Equities report. The moving annual total (MAT) for the month stood at 8.2% year-over-year, indicating sustained market expansion.
The growth drivers for November were primarily higher pricing, which contributed substantially, and new product launches. Volume contributions were also notable, standing at 160 basis points, an increase compared to the 30 basis points seen in the MAT from November last year. This suggests a balanced growth approach with increasing reliance on product volumes.
Financial Implications and Growth Drivers
Growth was broad-based across key therapeutic areas, with the exception of anti-infectives. The report projects an 8-16% year-over-year domestic sales growth for FY2026E for its coverage, underpinned by continued benefits from pricing strategies, new product introductions, and strategic acquisitions or in-licensing deals.
Chronic therapies led the expansion with a healthy 14% yearly growth, while acute therapies grew by 5%. Specific segments like oncology, cardiac, vaccines, anti-diabetic, urology, neuro, and gynaecology were major contributors to the overall pharmaceutical industry's growth trajectory. Multinational companies operating in India reported a robust 13.5% year-over-year revenue growth, significantly outpacing the 7.6% sales growth seen by domestic companies.
Market Reaction and Key Players
In terms of market share, Sun Pharmaceutical Industries Limited continued to hold the top position with ₹198 billion in MAT sales, commanding an 8.0% market share. Abbott India followed with ₹157 billion in sales and a 6.4% share. Cipla secured the third spot with ₹134 billion, largely driven by its strong performance in respiratory and chronic therapies. Mankind Pharma held a 4.8% market share with ₹118 billion in sales, showcasing its strength in cardiac therapies.
Other significant players rounding out the top ten in terms of MAT sales included Alkem Laboratories, Intas Pharmaceuticals, Lupin Limited, Macleods Pharmaceuticals, Dr. Reddy’s Laboratories, and Zydus Lifesciences. These companies represent the core of the Indian pharmaceutical landscape.
Underperformers and Market Share Shifts
However, the market also saw shifts, with several companies experiencing a decline in their market share over the preceding six months. Notable among these were FDC Limited, Abbott India, Mankind Pharma, Torrent Pharmaceuticals, USV Private Limited, Emcure Pharmaceuticals, JB Chemicals & Pharmaceuticals Limited, Ipca Laboratories, and Eris Lifesciences. Mounjaro remained the largest single brand by sales in November 2025, continuing its strong performance trend.
Risks and Future Outlook
A key risk highlighted in the report is the persistent traction of alternate sales channels, which is estimated to cause an annual dent of 120-160 basis points on branded IPM volume growth, potentially continuing until FY2028E. The rapid expansion of government initiatives like Jan Aushadhi, which now operates nearly 16,000 stores, poses a further risk of increasing this impact on the branded market.
Current domestic valuations appear to price in the ongoing steady decline in the share of branded generics. However, any further deterioration in this segment could lead to a downward revision of stock valuations, unless fundamental quality issues are effectively addressed.
Impact
This analysis provides critical insights into the performance and challenges of the Indian pharmaceutical sector. Investors can use this information to assess the growth prospects and risks associated with individual companies and the sector as a whole. The divergence in performance between MNCs and domestic players, along with the threat from alternate channels, offers crucial context for strategic investment decisions. The overall health of the pharmaceutical market is a significant indicator for the Indian economy.
Impact Rating: 8/10
Difficult Terms Explained
- YoY: Year-over-Year, a comparison of performance against the same period in the previous year.
- MAT: Moving Annual Total, the sum of sales over the preceding twelve months, used to smooth out short-term fluctuations and identify trends.
- bps: Basis Points, a unit of measure equal to one-hundredth of a percentage point (0.01%).
- Therapies: Medical treatments or categories of drugs designed to manage specific diseases or health conditions.
- MNCs: Multinational Corporations, companies that operate in multiple countries.
- IPM: Indian Pharmaceutical Market, referring specifically to the domestic market for pharmaceutical products within India.
- Branded Generics: These are generic drugs that are marketed under a specific brand name by a pharmaceutical company, often at a premium price compared to unbranded generics.